Pharming Group, a Dutch pharmaceutical company, has made a takeover bid for Abliva, valuing the company at 725 million SEK. The offer, priced at 0.45 SEK per share, represents a premium of 227%, marking it as the second highest premium for any bid since January 2017. The announcement has significantly impacted Abliva's stock, which surged by 215% following the news. Meanwhile, the broader Stockholm stock market, represented by the OMXS30 index, experienced a decline of 0.5% on December 17, 2024, continuing a downward trend amid various market pressures, including concerns over Intrum's debt restructuring efforts, which faced setbacks in negotiations with creditors. Intrum, Europe's largest debt collector, has been in discussions regarding its Chapter 11 restructuring plan but has recently failed to reach a settlement with a minority group of noteholders.